http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 01 Sep 2026 09:07:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR http://www.streetinsider.com/Analyst+PT+Change/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2420+at+RBC+Capital/26878206.html RBC Capital analyst Leonid Timashev raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $20.00 (from $19.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2420+at+RBC+Capital/26878206.html Thu, 06 Aug 2026 06:59:15 -0400 XNCR http://www.streetinsider.com/Earnings/Xencor+%28XNCR%29+Tops+Q2+EPS+by+51c/26873698.html <p>Xencor (NASDAQ: XNCR) reported Q2 EPS of ($0.29), $0.51 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $51.22 million versus the consensus estimate of $18.23 million.</p><p>For earnings history and earnings-related data on Xencor (XNCR) <a href="http://www.streetinsider.com/ec_earnings.php?q=XNCR">click here</a>.</p> http://www.streetinsider.com/Earnings/Xencor+%28XNCR%29+Tops+Q2+EPS+by+51c/26873698.html Wed, 05 Aug 2026 16:03:51 -0400 XNCR http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xencor+Inc++++++++++++++++For%3A+Jun+30/26873672.html si-local-file:///var/storage/secattach/20260805/26873672.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xencor+Inc++++++++++++++++For%3A+Jun+30/26873672.html Wed, 05 Aug 2026 16:02:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xencor+Inc++++++++++++++++For%3A+Jun+30/26873672.html si-local-file:///var/storage/secattach/20260805/26873672.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xencor+Inc++++++++++++++++For%3A+Jun+30/26873672.html Wed, 05 Aug 2026 16:02:00 -0400 O.00017340 XNCR http://www.streetinsider.com/Press+Releases/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html <p class="bwalignc"> -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- </p><p class="bwalignc"> -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week induction period expected in 2H27 -- </p><p class="bwalignc"> -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study open for enrollment -- </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended http://www.streetinsider.com/Press+Releases/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html Wed, 05 Aug 2026 16:01:00 -0400 O.00017340 XNCR http://www.streetinsider.com/Press+Releases/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html <p class="bwalignc"> -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- </p><p class="bwalignc"> -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week induction period expected in 2H27 -- </p><p class="bwalignc"> -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study open for enrollment -- </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended http://www.streetinsider.com/Press+Releases/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html Wed, 05 Aug 2026 16:01:00 -0400 O.00017340 XNCR http://www.streetinsider.com/Business+Wire/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html <p class="bwalignc"> -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- </p><p class="bwalignc"> -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week induction period expected in 2H27 -- </p><p class="bwalignc"> -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study open for enrollment -- </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended http://www.streetinsider.com/Business+Wire/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html Wed, 05 Aug 2026 16:01:00 -0400 O.00017340 XNCR http://www.streetinsider.com/Business+Wire/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html <p class="bwalignc"> -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- </p><p class="bwalignc"> -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week induction period expected in 2H27 -- </p><p class="bwalignc"> -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study open for enrollment -- </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended http://www.streetinsider.com/Business+Wire/Xencor+Reports+Second+Quarter+2026+Financial+Results/26873594.html Wed, 05 Aug 2026 16:01:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xencor+Inc++++++++++++++++For%3A+Aug+05/26873624.html si-local-file:///var/storage/secattach/20260805/26873624.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xencor+Inc++++++++++++++++For%3A+Aug+05/26873624.html Wed, 05 Aug 2026 16:01:00 -0400 O.00017340 XNCR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xencor+Inc++++++++++++++++For%3A+Aug+05/26873624.html si-local-file:///var/storage/secattach/20260805/26873624.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xencor+Inc++++++++++++++++For%3A+Aug+05/26873624.html Wed, 05 Aug 2026 16:01:00 -0400 O.00017340 XNCR http://www.streetinsider.com/Analyst+Comments/William+Blair+Updates+Analyst+Conviction+List+For+August+2026/26852679.html <p>William Blair Updates Analyst Conviction List For August 2026.</p><p>The analyst comments "The William Blair Analyst Conviction List is a bottom-up list published monthly. It has been compiled by requesting each analyst to select up to two of their highest-conviction stocks over the next six months. The objective is to identify nearer-term ideas where analysts have a high degree of conviction of strong performance. Our list is provided on page 2, sorted by market cap within sectors. Following the list, we provide a short rationale for any stock that has been added or removed for the coming month, links to any http://www.streetinsider.com/Analyst+Comments/William+Blair+Updates+Analyst+Conviction+List+For+August+2026/26852679.html Mon, 03 Aug 2026 05:23:20 -0400 AFRM AMPX CBZ CRDO CVNA CWK GEV GNRC HROW JLL LPLA MEC XNCR